Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Toxemia 1Primary Ovarian Insufficiency 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Glioblastoma 1Diabetes, Gestational 1Cardiovascular Diseases 1Brain Neoplasms 1

Interventions

Rituximab 25Lenalidomide 20Cyclophosphamide 18obinutuzumab 8Vincristine 8Doxorubicin 8Prednisone 7Bendamustine Hydrochloride 7tazemetostat 6ibrutinib 6Biopsy 6venetoclax 5pembrolizumab 5fludarabine 5Specimen Handling 5CT-P10 5fludarabine phosphate 4R-CHOP protocol 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Prednisolone 3Etoposide 3tocilizumab 2copanlisib 2axicabtagene ciloleucel 2atezolizumab 2acalabrutinib 2abexinostat 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Follicular × Positron-Emission Tomography × Clear all
NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
33 enrolled 17 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡